刘庆思教授论治骨质疏松症学术思想研究
|
摘要
目的：
首先以传承和发扬的思维对刘庆思教授学术思想做系统的分析、归纳和总结,其次对刘庆思教授论治的骨质疏松症理论加以整理和研究。为此拟以刘师中心学术思想的代表方骨康方进行本研究：1.通过动物实验观察对去卵巢大鼠血清活性维生素D和骨密度变化情况；2.通过临床研究观察骨康方对绝经后骨质疏松症患者和非骨质疏松症受试者血清活性维生素D和骨密度变化情况,并应用中药骨康对上述指标进行干预研究。试图揭示：(1)酶的活性,肾的强弱与骨质疏松症是否存在内在的必然的联系；(2)骨质疏松病症的轻重是否可通过1α-羟化酶的活性来表达；(3)从酶学角度探讨“肾主骨”的内涵,丰富和发展中医“肾主骨”理论；(4)从深层次的证明补肾壮骨、健脾益气、活血通络的治则及其代表方骨康防治骨质疏松症的有效性、科学性,实践性及其临床指导意义。
方法：
动物实验：健康雌性SD大鼠60只,4月龄,平均体重230±20g。随机分为对照组,模型组,罗盖全组,骨康组,共四组,每组15只。适应一周后,所有大鼠以2%戊巴比妥钠40mg/kg腹腔注射麻醉,然后打开腹腔,对照组切除小块脂肪,其余各组切除双侧卵巢。除对照组外,所有组均用Cdcl2液染毒90天。对照组同时用等量生理盐水,罗盖全组同时用罗盖全,骨康组同时用骨康灌胃,均为2ml,每天一次。处死前24h收集尿液。所有大鼠用2%戊巴比妥钠40mg/kg腹腔注射麻醉,收集血样。取3个部位计算骨密度,右胶骨颈(BMD1)、Ward区(BMD2)及2-4腰椎(BMD3)。血清雌二醇E2、25(OH)D3及1,25(OH)2D3测定。
临床研究：选取志愿参加本研究之绝经后妇女60人,分为非骨质疏松组和骨质疏松组,采用双能X线吸收法和放射免疫法测量两组骨密度和血清活性维生素D,进行相关性分析。
结果：
动物实验结果：
1.实验结束时共有48只大鼠进入最终实验统计。
2.各去卵巢组的股骨颈及腰椎骨密度均显著低于对照组,差异有显著意义(P<0.05);各去卵巢组组间比较无明显差异。
3.各去卵巢组的血清雌二醇水平显著低于对照组(P<0.05),表明去卵巢手术成功。
4.各组血清25(OH)D3水平无差异。各去卵巢大鼠组的血清1,25(OH)2D3水平显著低于对照组(P<0.05),表明镉接触可使1,25(OH)2D3水平下降,但不影响25(OH)D3。骨康使血中1,25(OH)2D3含量有所上升,虽统计上无显著性差异,但仍有临床意义。
5.各染毒组血、尿镉的对数值均高于对照组,并有显著性差异(P<0.05)。同时,血镉与尿镉之间有显著性相关。
6.与对照组相比,去卵巢大鼠的尿钙排泄增加,各染毒组的尿β2-MG和NAG水平升高,均高于对照组。骨康对受试大鼠肾功能有明显影响,这种影响是正面的,积极的。
临床研究结果：
1.服药前,两组间25(OH)D：3及1,25(OH)2D3,血清雌二醇,腰椎骨密度均有显著性差异(P<0.05)。这种差异表明骨质疏松组为绝经后骨质疏松症患者,非骨质疏松组为绝经后非骨质疏松症受试者。
2.服药6个月后,上述指标两组间无显著性差异,表明骨康能显著提高羟化酶活性,25(OH)D3及1,25(OH)2D3,血清雌二醇,腰椎骨密度均有增加。
3.骨质疏松组自身前后对比,上述指标有显著性差异。表明骨康能显著改善血中25(OH)D3及1,25(OH)2D3,血清雌二醇水平,促使骨密度增加。
结论：
动物实验结论：
1.骨康能增加骨密度,提高血中雌激素水平。
镉染毒去卵巢大鼠骨密度、血清雌二醇水平显著下降,提示羟化酶活性及雌激素受到明显影响：活性降低,合成减少。骨康能改善大鼠骨密度、血清雌二醇水平。这与骨康具有补肾作用及含有雌激素样物质有关。
2.骨康能提高羟化酶活性,促进活性维生素D合成。
各组血清25(011)D、3水平无差异。各去卵巢大鼠组的血清1,25(OH)2D.3水平显著低于对照组。显示镉染毒去卵巢大鼠羟化酶活性严重受到抑制,骨康虽不能根本改变1,25(OH)2D：3水平下降,但从数值上看有升高趋势,这可能与骨康作用于成骨细胞及肠上皮细胞及含有雌激素样物质有关,从而提高了肾外羟化酶活性,促进了活性维生素D的合成,但机理有待进一步探讨。
3.骨康能明显改善’肾功能,具有较强的补。肾功效。
骨康对于镉染毒大鼠的肾功能不能从根本上扭转,但大鼠的存活率、毛发,活动度及饮食均有明显改善,检测指标也有所改变。
临床研究结论：
1.骨质疏松症患者血清血清25(OH)D。及1,25(OH)2D3,血清雌二醇显著下降,骨密度亦降低。
绝经后骨质疏松症患者血清25(OH)D3及1,25(OH)2D3,血清雌二醇均显著下降,腰椎骨密度也显著下降,提示绝经后骨质疏松症发生时内在机制发生改变,导致了骨质疏松。
2.骨康能提高羟化酶活性,促进活性维生素D合成。骨康虽不能从根本上扭转血清1,25(OH)：D。水平降低,但能提高羟化酶的活性,促进活性维生素D合成。
3.骨康有较强的补肾功能,有较全面的协同作用。
骨康能整体上改善患者全身机能,能明显减轻腰背痛,使骨密度下降趋势延缓,羟化酶活性增加,活性维生素D合成增多。
4.骨康的补肾,健脾,活血的作用能够提高羟化酶的活性,延缓骨质疏松症的进程。
5.可能的机理是：骨康通过补肾,增强了肾中羟化酶的活性,促进了肾内活性维生素D的合成,参与调节钙磷代谢,延缓骨质疏松发生进程；骨康通过健脾,促进肠上皮细胞及肾外合成活性维生素D,促进肠钙吸收,成骨细胞活跃,延缓骨质疏松发展进程；骨康通过活血,促进肝藏血,脾统血,加速血液循环,促进肝内25(OH)D3合成,促进羟化酶活性,利于合成活性维生素D,延缓骨质疏松演变进程。肾强,脾健,血畅,羟化酶活,则骨质疏松缓,它们之间存在着内在的必然的联系。酶学角度探讨“肾主骨”的内涵,丰富和发展了中医“肾主骨”理论。
6.从深层次的证明补肾壮骨、健脾益气、活血通络的代表方骨康防治骨质疏松症的有效性、科学性,实践性及其临床指导意义。
Objective:
First, the heritage and development of the thinking of Professor Liu Qingsi academic thinking on systems analysis, and summarized, followed by Professor Liu Qingsi on the Treatment of osteoporosis in theory to be organized and studied. Center of this division is intended to Professor Liu on behalf of academic thinking side of the GuKang study:1. Observed by animal experiments in ovariectomized rat serum active vitamin D and bone mineral density changes;2. Clinical observations of GuKang by side osteoporosis in postmenopausal osteoporosis patients and non-active subjects serum vitamin D and bone mineral density changes, and apply these indicators GuKang intervention study. To reveal:(1) enzyme activity, the strength of the kidney and the presence of osteoporosis within the necessary link;(2) whether the severity of the disease osteoporosis through the activity of1α-hydroxylase expression;(3) From the enzymatic point of view of "renal bone" meaning, enrichment and development of Chinese "kidneys bone" theory;(4) proof of Bushenzhuanggu deeper, spleen qi, promoting blood circulation network of the rule is GuKang and their representatives, parties of the effectiveness of osteoporosis prevention and treatment, scientific, practical and clinical significance.
Method:
Animal experiments:60healthy female SD rats,4months old, average weight of230±20g. Randomly divided into control group, model group, Lo cover the whole group, GuKang group, a total of four groups of15. Meet a week later, all rats with2%pentobarbital sodium40mg/kg intraperitoneal injection of anesthesia, and then open the abdominal cavity, removal of small pieces of fat control group, the rest of the group ovariectomized. In addition to the control group, all groups were exposed to90days with Cdcl2liquid. While the control group with normal saline, with Lo Lo cover the whole group at the same time cover the whole, while GuKang group fed with GuKang.24h collection of urine before death.2%of all rats with40mg/kg intraperitoneal injection of sodium pentobarbital anesthesia to collect blood samples. Take three parts of the calculation of bone mineral density, right femoral neck (BMD1), Ward District (BMD2) and2-4lumbar spine (BMD3). Serum estradiol E2,25(OH) D3and1,25(OH)2D3measured.
Clinical study:select volunteers to participate in this study of60postmenopausal women, into Non-osteoporosis group and osteoporosis group, using dual-energy X-ray absorption spectrometry and radioimmunoassay measurement of bone mineral density and serum activity of two groups of vitamin D, the correlation analysis.
Results:
Animal experiments:
1.End of the experiment a total of48rats into the final test statistics.
2.The OVX group BMD of femoral neck and lumbar spine were significantly lower than the control group, the difference was significant (P<0.05); the ovariectomized group showed no significant difference between groups.
3. Groups of ovariectomized estradiol levels were significantly lower than the control group (P<0.05), that the success of ovariectomy surgery.
4.The serum25(OH)D3levels were not different. The group of ovariectomized rats, serum1,25(OH)2D3levels were significantly lower than the control group (P<0.05), showed that cadmium exposure can make1,25(OH)2D3levels drop, but does not affect25(OH)D3. GuKang in the blood1,25(OH)2D3levels increased, although no statistically significant difference, but there are still clinical significance.
5. The exposure group blood and urine of cadmium values were higher, and there was significant difference (P<0.05). Meanwhile, the blood cadmium and urine cadmium were significantly correlated.
6. Compared with the control group, ovariectomized rats increases urinary calcium excretion, urinary each exposure group, β2-MG and NAG levels, were higher. GuKang on renal function subjects had a significant effect, this effect is positive, positive.
Clinical findings:
1. Before treatment between the two groups25(OH)D3and1,25(OH)2D3, serum estradiol and lumbar bone mineral density were significantly different (P <0.05). This difference shows that postmenopausal osteoporotic group of patients with osteoporosis, non-osteoporotic group, non-osteoporosis in postmenopausal subjects.
2.6months after medication, these indicators between the two groups no significant differences, indicating that GuKang can significantly increase hydroxylase activity,25(OH)D3and1,25(OH)2D3, serum estradiol and lumbar bone density has increased.
3. Before and after their osteoporosis group, these indicators have significant differences. That can significantly improve GuKang in the blood25(OH)D3and1,25(OH)2D3, serum estradiol levels, prompting increased bone mineral density.
Conclusion:
Animal experimental results:
1. GuKang can increase bone density, increased levels of estrogen in the blood.
Bone mineral density in ovariectomized rats exposed to cadmium, serum estradiol levels were significantly decreased, suggesting that estrogen hydroxylase activity and significantly affected:decreased activity, decreased synthesis. GuKang can improve bone mineral density, serum estradiol levels. This is a kidney function and GuKang contain estrogen-like substances.2. Hydroxylase activity can improve GuKang and promote active vitamin D synthesis.
The serum25(OH)D3levels were not different. The group of ovariectomized rats, serum1,25(OH)2D3levels were significantly lower than the control group. Cadmium exposure in ovariectomized rats show hydroxylase activity severely inhibited, GuKang, although not fundamentally change the1,25(OH)2D3levels decreased, but tended to increase the value point of view, which may be applied to GuKang bone cells and intestinal epithelial cells and contain estrogen-like substances, resulting in improved renal hydroxylase activity, and promote the active vitamin D synthesis, but the mechanism needs further study.
3. GuKang can significantly improve renal function, kidney has a strong effect.
GuKang for renal function in rats exposed to cadmium can not radically change, but the survival rate of rats, hair, activity and diet were significantly improved detection of targets have changed.
Clinical findings:
1. Osteoporosis patients serum25(OH) D3andl,25(OH)2D3, significantly decreased serum estradiol, bone density is also reduced.
Postmenopausal osteoporosis in patients with serum25(OH)D3and1,25(OH)2D3, serum estradiol were significantly decreased, lumbar spine bone mineral density also decreased significantly, suggesting that post-menopausal osteoporosis occurs, the internal mechanism of change, triggered osteoporosi s.
2. Hydroxylase activity can improve GuKang and promote active vitamin D synthesis.
GuKang, while not fundamentally reverse the serum1,25(OH)2D3levels decreased, but can improve the hydroxylase activity, and promote active vitamin D synthesis.
3. Strong GuKang kidney function, a more comprehensive synergy.
GuKang can improve the patients overall body function, can significantly reduce back pain, bone density decline to slow down, hydroxylase activity increased, active vitamin D synthesis increased.
4. GuKang through the kidney, spleen, blood and thus can improve the hydroxylase activity, slow down the process of osteoporosis.
5. Possible mechanisms are:GuKang through the kidney, strengthen the kidney hydroxylase activity, and promote the activity of renal vitamin D synthesis, involved in the regulation of calcium and phosphorus metabolism, delaying the process of osteoporosis; GuKang through health spleen, and promote intestinal and renal epithelial cells outside the synthesis of active vitamin D, to promote intestinal calcium absorption, bone cell activity, slow down the process of development of osteoporosis; GuKang through blood circulation, promote liver blood, spleen blood, accelerate blood circulation, promote hepatic synthesis of25(OH)D3to promote hydroxylase activity, which will help synthetic activity of vitamin D, osteoporosis slow process of evolution. Strong kidney, spleen health, blood smooth, hydroxylase activity, the slow osteoporosis, among them there is an inherent and inevitable contact. Enzymatic point of view of "renal bone" meaning, enrichment and development of the Chinese "Kidneys bone" theory.
6. Deeper proof Bushenzhuanggu, spleen Qi, activating blood and GuKang network of representatives of parties the effectiveness of osteoporosis prevention and treatment, scientific, practical and clinical significance.
首先以传承和发扬的思维对刘庆思教授学术思想做系统的分析、归纳和总结,其次对刘庆思教授论治的骨质疏松症理论加以整理和研究。为此拟以刘师中心学术思想的代表方骨康方进行本研究：1.通过动物实验观察对去卵巢大鼠血清活性维生素D和骨密度变化情况；2.通过临床研究观察骨康方对绝经后骨质疏松症患者和非骨质疏松症受试者血清活性维生素D和骨密度变化情况,并应用中药骨康对上述指标进行干预研究。试图揭示：(1)酶的活性,肾的强弱与骨质疏松症是否存在内在的必然的联系；(2)骨质疏松病症的轻重是否可通过1α-羟化酶的活性来表达；(3)从酶学角度探讨“肾主骨”的内涵,丰富和发展中医“肾主骨”理论；(4)从深层次的证明补肾壮骨、健脾益气、活血通络的治则及其代表方骨康防治骨质疏松症的有效性、科学性,实践性及其临床指导意义。
方法：
动物实验：健康雌性SD大鼠60只,4月龄,平均体重230±20g。随机分为对照组,模型组,罗盖全组,骨康组,共四组,每组15只。适应一周后,所有大鼠以2%戊巴比妥钠40mg/kg腹腔注射麻醉,然后打开腹腔,对照组切除小块脂肪,其余各组切除双侧卵巢。除对照组外,所有组均用Cdcl2液染毒90天。对照组同时用等量生理盐水,罗盖全组同时用罗盖全,骨康组同时用骨康灌胃,均为2ml,每天一次。处死前24h收集尿液。所有大鼠用2%戊巴比妥钠40mg/kg腹腔注射麻醉,收集血样。取3个部位计算骨密度,右胶骨颈(BMD1)、Ward区(BMD2)及2-4腰椎(BMD3)。血清雌二醇E2、25(OH)D3及1,25(OH)2D3测定。
临床研究：选取志愿参加本研究之绝经后妇女60人,分为非骨质疏松组和骨质疏松组,采用双能X线吸收法和放射免疫法测量两组骨密度和血清活性维生素D,进行相关性分析。
结果：
动物实验结果：
1.实验结束时共有48只大鼠进入最终实验统计。
2.各去卵巢组的股骨颈及腰椎骨密度均显著低于对照组,差异有显著意义(P<0.05);各去卵巢组组间比较无明显差异。
3.各去卵巢组的血清雌二醇水平显著低于对照组(P<0.05),表明去卵巢手术成功。
4.各组血清25(OH)D3水平无差异。各去卵巢大鼠组的血清1,25(OH)2D3水平显著低于对照组(P<0.05),表明镉接触可使1,25(OH)2D3水平下降,但不影响25(OH)D3。骨康使血中1,25(OH)2D3含量有所上升,虽统计上无显著性差异,但仍有临床意义。
5.各染毒组血、尿镉的对数值均高于对照组,并有显著性差异(P<0.05)。同时,血镉与尿镉之间有显著性相关。
6.与对照组相比,去卵巢大鼠的尿钙排泄增加,各染毒组的尿β2-MG和NAG水平升高,均高于对照组。骨康对受试大鼠肾功能有明显影响,这种影响是正面的,积极的。
临床研究结果：
1.服药前,两组间25(OH)D：3及1,25(OH)2D3,血清雌二醇,腰椎骨密度均有显著性差异(P<0.05)。这种差异表明骨质疏松组为绝经后骨质疏松症患者,非骨质疏松组为绝经后非骨质疏松症受试者。
2.服药6个月后,上述指标两组间无显著性差异,表明骨康能显著提高羟化酶活性,25(OH)D3及1,25(OH)2D3,血清雌二醇,腰椎骨密度均有增加。
3.骨质疏松组自身前后对比,上述指标有显著性差异。表明骨康能显著改善血中25(OH)D3及1,25(OH)2D3,血清雌二醇水平,促使骨密度增加。
结论：
动物实验结论：
1.骨康能增加骨密度,提高血中雌激素水平。
镉染毒去卵巢大鼠骨密度、血清雌二醇水平显著下降,提示羟化酶活性及雌激素受到明显影响：活性降低,合成减少。骨康能改善大鼠骨密度、血清雌二醇水平。这与骨康具有补肾作用及含有雌激素样物质有关。
2.骨康能提高羟化酶活性,促进活性维生素D合成。
各组血清25(011)D、3水平无差异。各去卵巢大鼠组的血清1,25(OH)2D.3水平显著低于对照组。显示镉染毒去卵巢大鼠羟化酶活性严重受到抑制,骨康虽不能根本改变1,25(OH)2D：3水平下降,但从数值上看有升高趋势,这可能与骨康作用于成骨细胞及肠上皮细胞及含有雌激素样物质有关,从而提高了肾外羟化酶活性,促进了活性维生素D的合成,但机理有待进一步探讨。
3.骨康能明显改善’肾功能,具有较强的补。肾功效。
骨康对于镉染毒大鼠的肾功能不能从根本上扭转,但大鼠的存活率、毛发,活动度及饮食均有明显改善,检测指标也有所改变。
临床研究结论：
1.骨质疏松症患者血清血清25(OH)D。及1,25(OH)2D3,血清雌二醇显著下降,骨密度亦降低。
绝经后骨质疏松症患者血清25(OH)D3及1,25(OH)2D3,血清雌二醇均显著下降,腰椎骨密度也显著下降,提示绝经后骨质疏松症发生时内在机制发生改变,导致了骨质疏松。
2.骨康能提高羟化酶活性,促进活性维生素D合成。骨康虽不能从根本上扭转血清1,25(OH)：D。水平降低,但能提高羟化酶的活性,促进活性维生素D合成。
3.骨康有较强的补肾功能,有较全面的协同作用。
骨康能整体上改善患者全身机能,能明显减轻腰背痛,使骨密度下降趋势延缓,羟化酶活性增加,活性维生素D合成增多。
4.骨康的补肾,健脾,活血的作用能够提高羟化酶的活性,延缓骨质疏松症的进程。
5.可能的机理是：骨康通过补肾,增强了肾中羟化酶的活性,促进了肾内活性维生素D的合成,参与调节钙磷代谢,延缓骨质疏松发生进程；骨康通过健脾,促进肠上皮细胞及肾外合成活性维生素D,促进肠钙吸收,成骨细胞活跃,延缓骨质疏松发展进程；骨康通过活血,促进肝藏血,脾统血,加速血液循环,促进肝内25(OH)D3合成,促进羟化酶活性,利于合成活性维生素D,延缓骨质疏松演变进程。肾强,脾健,血畅,羟化酶活,则骨质疏松缓,它们之间存在着内在的必然的联系。酶学角度探讨“肾主骨”的内涵,丰富和发展了中医“肾主骨”理论。
6.从深层次的证明补肾壮骨、健脾益气、活血通络的代表方骨康防治骨质疏松症的有效性、科学性,实践性及其临床指导意义。
Objective:
First, the heritage and development of the thinking of Professor Liu Qingsi academic thinking on systems analysis, and summarized, followed by Professor Liu Qingsi on the Treatment of osteoporosis in theory to be organized and studied. Center of this division is intended to Professor Liu on behalf of academic thinking side of the GuKang study:1. Observed by animal experiments in ovariectomized rat serum active vitamin D and bone mineral density changes;2. Clinical observations of GuKang by side osteoporosis in postmenopausal osteoporosis patients and non-active subjects serum vitamin D and bone mineral density changes, and apply these indicators GuKang intervention study. To reveal:(1) enzyme activity, the strength of the kidney and the presence of osteoporosis within the necessary link;(2) whether the severity of the disease osteoporosis through the activity of1α-hydroxylase expression;(3) From the enzymatic point of view of "renal bone" meaning, enrichment and development of Chinese "kidneys bone" theory;(4) proof of Bushenzhuanggu deeper, spleen qi, promoting blood circulation network of the rule is GuKang and their representatives, parties of the effectiveness of osteoporosis prevention and treatment, scientific, practical and clinical significance.
Method:
Animal experiments:60healthy female SD rats,4months old, average weight of230±20g. Randomly divided into control group, model group, Lo cover the whole group, GuKang group, a total of four groups of15. Meet a week later, all rats with2%pentobarbital sodium40mg/kg intraperitoneal injection of anesthesia, and then open the abdominal cavity, removal of small pieces of fat control group, the rest of the group ovariectomized. In addition to the control group, all groups were exposed to90days with Cdcl2liquid. While the control group with normal saline, with Lo Lo cover the whole group at the same time cover the whole, while GuKang group fed with GuKang.24h collection of urine before death.2%of all rats with40mg/kg intraperitoneal injection of sodium pentobarbital anesthesia to collect blood samples. Take three parts of the calculation of bone mineral density, right femoral neck (BMD1), Ward District (BMD2) and2-4lumbar spine (BMD3). Serum estradiol E2,25(OH) D3and1,25(OH)2D3measured.
Clinical study:select volunteers to participate in this study of60postmenopausal women, into Non-osteoporosis group and osteoporosis group, using dual-energy X-ray absorption spectrometry and radioimmunoassay measurement of bone mineral density and serum activity of two groups of vitamin D, the correlation analysis.
Results:
Animal experiments:
1.End of the experiment a total of48rats into the final test statistics.
2.The OVX group BMD of femoral neck and lumbar spine were significantly lower than the control group, the difference was significant (P<0.05); the ovariectomized group showed no significant difference between groups.
3. Groups of ovariectomized estradiol levels were significantly lower than the control group (P<0.05), that the success of ovariectomy surgery.
4.The serum25(OH)D3levels were not different. The group of ovariectomized rats, serum1,25(OH)2D3levels were significantly lower than the control group (P<0.05), showed that cadmium exposure can make1,25(OH)2D3levels drop, but does not affect25(OH)D3. GuKang in the blood1,25(OH)2D3levels increased, although no statistically significant difference, but there are still clinical significance.
5. The exposure group blood and urine of cadmium values were higher, and there was significant difference (P<0.05). Meanwhile, the blood cadmium and urine cadmium were significantly correlated.
6. Compared with the control group, ovariectomized rats increases urinary calcium excretion, urinary each exposure group, β2-MG and NAG levels, were higher. GuKang on renal function subjects had a significant effect, this effect is positive, positive.
Clinical findings:
1. Before treatment between the two groups25(OH)D3and1,25(OH)2D3, serum estradiol and lumbar bone mineral density were significantly different (P <0.05). This difference shows that postmenopausal osteoporotic group of patients with osteoporosis, non-osteoporotic group, non-osteoporosis in postmenopausal subjects.
2.6months after medication, these indicators between the two groups no significant differences, indicating that GuKang can significantly increase hydroxylase activity,25(OH)D3and1,25(OH)2D3, serum estradiol and lumbar bone density has increased.
3. Before and after their osteoporosis group, these indicators have significant differences. That can significantly improve GuKang in the blood25(OH)D3and1,25(OH)2D3, serum estradiol levels, prompting increased bone mineral density.
Conclusion:
Animal experimental results:
1. GuKang can increase bone density, increased levels of estrogen in the blood.
Bone mineral density in ovariectomized rats exposed to cadmium, serum estradiol levels were significantly decreased, suggesting that estrogen hydroxylase activity and significantly affected:decreased activity, decreased synthesis. GuKang can improve bone mineral density, serum estradiol levels. This is a kidney function and GuKang contain estrogen-like substances.2. Hydroxylase activity can improve GuKang and promote active vitamin D synthesis.
The serum25(OH)D3levels were not different. The group of ovariectomized rats, serum1,25(OH)2D3levels were significantly lower than the control group. Cadmium exposure in ovariectomized rats show hydroxylase activity severely inhibited, GuKang, although not fundamentally change the1,25(OH)2D3levels decreased, but tended to increase the value point of view, which may be applied to GuKang bone cells and intestinal epithelial cells and contain estrogen-like substances, resulting in improved renal hydroxylase activity, and promote the active vitamin D synthesis, but the mechanism needs further study.
3. GuKang can significantly improve renal function, kidney has a strong effect.
GuKang for renal function in rats exposed to cadmium can not radically change, but the survival rate of rats, hair, activity and diet were significantly improved detection of targets have changed.
Clinical findings:
1. Osteoporosis patients serum25(OH) D3andl,25(OH)2D3, significantly decreased serum estradiol, bone density is also reduced.
Postmenopausal osteoporosis in patients with serum25(OH)D3and1,25(OH)2D3, serum estradiol were significantly decreased, lumbar spine bone mineral density also decreased significantly, suggesting that post-menopausal osteoporosis occurs, the internal mechanism of change, triggered osteoporosi s.
2. Hydroxylase activity can improve GuKang and promote active vitamin D synthesis.
GuKang, while not fundamentally reverse the serum1,25(OH)2D3levels decreased, but can improve the hydroxylase activity, and promote active vitamin D synthesis.
3. Strong GuKang kidney function, a more comprehensive synergy.
GuKang can improve the patients overall body function, can significantly reduce back pain, bone density decline to slow down, hydroxylase activity increased, active vitamin D synthesis increased.
4. GuKang through the kidney, spleen, blood and thus can improve the hydroxylase activity, slow down the process of osteoporosis.
5. Possible mechanisms are:GuKang through the kidney, strengthen the kidney hydroxylase activity, and promote the activity of renal vitamin D synthesis, involved in the regulation of calcium and phosphorus metabolism, delaying the process of osteoporosis; GuKang through health spleen, and promote intestinal and renal epithelial cells outside the synthesis of active vitamin D, to promote intestinal calcium absorption, bone cell activity, slow down the process of development of osteoporosis; GuKang through blood circulation, promote liver blood, spleen blood, accelerate blood circulation, promote hepatic synthesis of25(OH)D3to promote hydroxylase activity, which will help synthetic activity of vitamin D, osteoporosis slow process of evolution. Strong kidney, spleen health, blood smooth, hydroxylase activity, the slow osteoporosis, among them there is an inherent and inevitable contact. Enzymatic point of view of "renal bone" meaning, enrichment and development of the Chinese "Kidneys bone" theory.
6. Deeper proof Bushenzhuanggu, spleen Qi, activating blood and GuKang network of representatives of parties the effectiveness of osteoporosis prevention and treatment, scientific, practical and clinical significance.
引文
[1]薛延.骨质疏松症防治指南[M].北京：人民卫生出版社,2008；8：14-15.
[2]Robert. F. K, John. A, Zafrira. A, et al. Regulation of bone mass in mice by the lipoxygenase gene Alox15[J]. Science,2004;303:229-232.
[3]Harada. S. I, Rodan. G. A. Control of osteoblast function and regulation of bone mass [J]. Nature,2003;423:349-355.
[4]秦岭,张戈,等译.美国国家卫生院有关骨质疏松症的预防、诊断和治疗的共识文件[J].中国骨质疏松杂志,2002；8(1)：90-93.
[5]薛延.骨质疏松症的流行病学概况[J].新医学,2007；38(1)：7-8.
[6]吴雪茹,施佳平,徐必达,等.骨康口服液工艺优化研究[J].中成药,1999,21(5)：218-220.
[7]曾惠芳,苏子仁,刘庆思.骨康口服液中补骨脂素、异补骨脂素的含量测定[J].中药新药与临床药理,1999,10(4)：237-239.
[8]吴雪茹,施佳平,涂兴明.十味骨康口服液的质量标准研究[J].中药材,2008,31(8)：1264-1266.
[9]刘庆思,庄洪,黄宏兴,等.补肾、健脾、活血法防治骨质疏松症的系列研究技术资料,2002年10月.
[10]邵敏,黄宏兴,庄洪.骨康防治骨质疏松拆方的初步研究[J].中国中医骨伤科杂志,2000,8(2)：7-8.
[11]邵敏,刘庆思,赵静.中药骨康防治维甲酸造成大鼠骨质疏松的研究[J].湖南中医学院学报,2000,20(2)：16-17.
[12]牛维,刘庆思,邵敏.骨康防治实验性骨质疏松症的骨组织计量学观察[J].中医正骨,2001,1 3(5)：13-14.
[13]熊学华,余克强,刘庆思.中药骨康对去势大鼠骨吸收与骨形成影响的实验研究[J].现代康复,2001,5(22)：13-14.
[14]卿茂盛,余阗,刘庆思等.中药骨康预防去势大鼠骨质疏松症的实验研究[J].中国中医药科技,2002,9(4)：212-213.
[15]林一峰,魏合伟,蔡桦等.骨康及其含药血清中类性激素样物质含量的测定[J].中医药学刊,2003,21(5)：663-664.
[16]魏合伟,李钊,庄洪等.中药骨康含药血清对TNF-α致大鼠成骨细胞凋亡的影响[J].中医正骨,2005,17(3)：6-8.
[17]魏合伟,李钊.骨康含药血清对新生大鼠成骨细胞碱性磷酸酶活性的影响[J].中医药学刊,2005,23(1)：77-78.
[18]林一峰,刘庆思.骨康含药血清对成骨细胞PDGF-AA表达影响的实验研究[J].中国骨质疏松杂志,2006,12(5)：459-461.
[19]MarcJ, PrezeljJ, KomelR, et al. Association of vitamin-D receptor gene polymorphism with bone mineral density in Slovenian postmenopausal women[J]. Gynecol Endocrinol,2000; 14(1):60-64.
[20]Munger RG, CerhanJR, ChivBC. Prospective study of dietary protein in take and risk of hip fracture in postmenopausal women[J]. Am J Clin Nutr,1999; 69(1):147-152.
[21]Bailey, D. A., H. A. McKay, R. L. Mirwald, P. R. E. Crocker, et al. A six-year longitudinal study of the relationship of physical activity to bone mineral accrual in growing children:the University of Saskatchewan Bone Mineral Accrual Study [J]. Bone Miner Res,1999:14(6):1672.
[22]Blum M.Harris SS, Must A, et al. Leptin body composition and bone mineral density in preemenopausal women[J]. Calcif Tissue Int,2003;Apr14[epub ahead of print].
[23]Yahata Y, Aoyagi K,Okano K,et al. Mineral density,body mass index and lifestyle among postmenopausal Japanese women:relationship of body[J]. Tohoku J Exp Med,2002,196 (3):123-129.
[24]郭永忠,张峰.尿脱氧吡啶啉时新的骨吸收生化指标[J].医学综述,2000;6(1)：7-9.
[25]陶耕,蔡俊峰,李永加.绝经后妇女血清骨代谢生化指标的变化及意义[J].福建医药杂志,2003：25(1)：26-27.
[26]Vanderschueren D, VanHerck E, Suiker AMH, et al. Bone and mineral metabolism in aged rats:Short and long term effects of androgen deficiency[J]. Endocrinology,1992; 130: 2906-2916.
[27]周维,周丽萍,彭文湃.HRT加用雄激素对绝经后妇女骨代谢影响的探讨[J].中国妇幼保健,2004;19(1)：16-18.
[28]冯有辉,许碧连,何康等.大鼠骨量影响因素的灰色关联分析[J].中国新医药,2004;3(10)：43-44.
[29]Drake FH Dedds RA, James IE, et al. Cathepsin K, but not cathepsin B, L, or S, is abundantly expressed in human osteoclests[J]. Biol Chem,1996,271(21):12511-12516.
[30]RamazaT, Goto T, Kamiya T, et al. Study of immunoelectren micm-scopic localization of cathepsin K in osteoclasts and other bone eeHsinthemousefemur[J]. Bone,1998,23(6): 499-509.
[31]郭凌岑,龚健.绝经后骨质疏松症治疗进展[J].中国妇产科临床杂志,2006,7(6)：469-470.
[32]杨玲,殷晓进.锶与骨矿代谢[J].中国骨质疏松杂志,2004,3(8)：384-386.
[33]刘忠厚,潘子昂,王石麟,等.骨骼生长衰老规律和原发性骨质疏松预诊的研究[J].中国骨质疏松杂志,1995(1)：1-7.
[34]丁桂芝.从骨矿含量变化规律看肾主骨理论的科学性[J].湖北中医杂志,1991,13(2)：27-29.
[35]王大健,王爱坚, 黄李平,等.探讨老年肾虚证与骨密度的关系[J].上海中医药杂志,2002,36(9)： 35-36.
[36]陈训华,郭振芳,张万强.骨丢失与肾虚证的相关研究[J].中国中医药信息杂志,2002,9(10)： 21-22.
[37]朱小华,赵仓焕.从脾胃论治骨质疏松症[J].新中医,2004,36(12)： 3-4.
[38]孟晓东.补肾健脾养胃法治疗骨质疏松症的临床观察[J].吉林中医药,2004,24(11)29.
[39]袁静,章薇,金华,等.养血调肝方对绝经后骨质疏松症影响的实验研究[J].中国中医骨伤科杂志,2008,16(9)32-34.
[40]赵治友,邬亚军.骨质疏松症的中医辨证思路与治法研究[J].浙江中医药大学学报,2007,31(3)：275-276.
[41]徐元雯.管窥肝郁证的现代研究[J].江西中医学院学报,2007,19(2)：99-100.
[42]文哲双,王志忠,朱毅.肝郁患者血清T、E2、PRL检测及其临床意义[J].湖北中医学院学报,2000,2(2)：27-29.
[43]滕秀香.122例卵巢早衰患者中医证候分析及致病因素调查[J].中国中医药信息杂志,2008,15(4)： 18-20.
[44]吴笛, 陈日辉,方锦鎏.调补肝肾法为主治疗老年性骨质疏松症31例[J].山东中医药大学学报,2008,32(2)：126-127.
[45]郭郡浩,蔡辉.从瘀论治原发性骨质疏松症研究进展[J].河北中医,2008,30(11)：1225-1227.
[46]眭承志,周军,刘志坤.绝经后骨质疏松症血瘀病机的客观初步论证[J].中医研究,2005,18(1)：30-33.
[47]熊辉,姚共和,祁开泽,等.强肾密骨液电渗对原发性骨质疏松症骨代谢的影响[J].中国中医骨伤科杂志,2002,10(2)：17-20.
[48]廖琳,黎学松,蔡全辉,等.补肾生髓法治疗绝经后骨质疏松症的临床研究[J].中国中医药信息杂志,2004,11(4)：287-289.
[49]张红.从补肾健脾法谈中医药对骨质疏松症的防治[J].时珍国医国药,2007,18(9)：2250.
[50]黄振俊,陈建新,白一冰.滋肾骨康丸治疗骨质疏松症的临床研究[J].生物技术通讯,2008,19(2)：263-264.
[51]咎强,朱超,屈强,等.强骨汤治疗肾虚型骨质疏松症56例[J].陕西中医,2006,27(8)：957-958.
[52]阎小萍,朱俊岭,颜珏,等.补肾强督方治疗强直性脊柱炎骨质疏松、骨量减少102例临床观察[J].中华中医药杂志,2007,22(8)：571-573.
[53]周忠民,安建武,张根印.双骨汤治疗骨质疏松性骨折48例[J].陕西中医,2006,27(12)：1503-1505.
[54]文朝,王新,方楚权,等.壮骨胶囊治疗绝经后骨质疏松症的临床观察[J].湖北中医杂志,2008,30(8)：15-16.
[55]罗换新,赵学文,冀海源,等.壮骨颗粒治疗原发性骨质疏松症的多中心随机对照[J].辽宁中医杂志,2008,35(7)：1037-1038.
[56]林一峰.补肾中药对绝经后骨质疏松症患者密度、血清骨保护素和肿瘤坏死因子a的影响[J].中国临床康复,2006,10(27)：51-53.
[57]刘海全,陈超.刘庆思教授治疗骨质疏松症经验介绍[J].新中医,2007,39(5)：14.
[58]邓伟民,崔伟历,贺扬淑,等.补肾壮骨冲剂对男性骨质疏松症患者骨矿含量和骨密度的影响：5年观察[J].中国临床康复,2005,9(11)：150-151.
[59]史晓,祁丽丽,杨文宏.补肾通络方治疗原发性骨质疏松症32例[J].陕西中医,2007,28(11)：1497-1499.
[60]黄永明,许少健,石宇雄,等.骨松安胶囊治疗绝经后骨质疏松症34例[J].陕西中医,2006,27(8)：954-956.
[61]马泉,刘瑞荣,杨印智.骨疏康治疗绝经后骨质疏松症86例[J].陕西中医,2004,25(12)：1096-1097.
[62]许旺,陈玉辰,张景凤.益肾养肝合剂治疗肝肾不足型绝经后骨质疏松症临床疗效观察[J].中草药,2005,36(6)：898-899.
[63]李茵,于高路,莫少强,等.灰关联分析及信息处理方法评价骨质疏松症复方中药治疗的用药规律[J].中国组织工程研究与临床康复,2007,11(35)：7065-7068.
[64]Koji Nogawa, Ikiko Tsuritani, Teruhiko Kido, et al. Mechanism for bone disease found in inhabitants environmentally exposed to cadmium:decreased serum 1 α,25- dihydroxy vitamin D level[J].Int Occup Environ Health,1987,59:21.
[65]Feldman SL, Cousin J. Influence of cadmium on the metabolism of 25-hydroxylchole calciferol in chicks[J]. Nutr Re p Int,1973,8:251.
[66]Lorentzon R., Larsson S. E.. Vitamin D metabolism in rats at low and normal calcium intake and the effect of cadmium exposure[J]. Physical Science and Molecular Medicine, 1977,53:439.
[67]Chalkley S R, Richmond J, Bar It rop D. Measurement of vitamin D3 metabolites in smelter workers ex posed to lead and cadmium[J]. Occup Environ Med,1998,55:446.
[68]Ikiko Tsuritani, Ryumon Honda, Masao Ishizaki, et al. Impairment of vitamin D metabolism due to environmental cadmium exposure, and possible relevance to sex related to the bone damage[J]. Toxicol and Environ Health,1992,37:519.
[69]Cummings SR, Browner WS, Bauer D, et al. Endogenous hormones and the risk of hip and vertebral fractures among older women. Study of Osteoporotic Fractures Research Group[J]. N Engl J Med,1998,339:733-738.
[70]Melin AL, Wilske J, Ringerta H, et al. Vitamin D status, parathyroid function and femoral bone density in an elderly Swedish population living at home[J]. Aging Milano, 1999,11:200-207.
[71]Bettica P, Bevilacqua M, Vag o T, et al. High prevalence of hypovitaminosis D among free living postmenopausal women referred to an osteoporosis outpatient clinic in northern Italy for initial screening[J]. Osteoporos Int,1999,9:226-229.
[72]Gallagher JC, Fowler SE, Detter JR, et al. Combination treatment with Estrogen and calcitriol in the prevention of age related bone loss[J]. Clin Endocrinol Metab, 2001,86:3618-3628.
[2]Robert. F. K, John. A, Zafrira. A, et al. Regulation of bone mass in mice by the lipoxygenase gene Alox15[J]. Science,2004;303:229-232.
[3]Harada. S. I, Rodan. G. A. Control of osteoblast function and regulation of bone mass [J]. Nature,2003;423:349-355.
[4]秦岭,张戈,等译.美国国家卫生院有关骨质疏松症的预防、诊断和治疗的共识文件[J].中国骨质疏松杂志,2002；8(1)：90-93.
[5]薛延.骨质疏松症的流行病学概况[J].新医学,2007；38(1)：7-8.
[6]吴雪茹,施佳平,徐必达,等.骨康口服液工艺优化研究[J].中成药,1999,21(5)：218-220.
[7]曾惠芳,苏子仁,刘庆思.骨康口服液中补骨脂素、异补骨脂素的含量测定[J].中药新药与临床药理,1999,10(4)：237-239.
[8]吴雪茹,施佳平,涂兴明.十味骨康口服液的质量标准研究[J].中药材,2008,31(8)：1264-1266.
[9]刘庆思,庄洪,黄宏兴,等.补肾、健脾、活血法防治骨质疏松症的系列研究技术资料,2002年10月.
[10]邵敏,黄宏兴,庄洪.骨康防治骨质疏松拆方的初步研究[J].中国中医骨伤科杂志,2000,8(2)：7-8.
[11]邵敏,刘庆思,赵静.中药骨康防治维甲酸造成大鼠骨质疏松的研究[J].湖南中医学院学报,2000,20(2)：16-17.
[12]牛维,刘庆思,邵敏.骨康防治实验性骨质疏松症的骨组织计量学观察[J].中医正骨,2001,1 3(5)：13-14.
[13]熊学华,余克强,刘庆思.中药骨康对去势大鼠骨吸收与骨形成影响的实验研究[J].现代康复,2001,5(22)：13-14.
[14]卿茂盛,余阗,刘庆思等.中药骨康预防去势大鼠骨质疏松症的实验研究[J].中国中医药科技,2002,9(4)：212-213.
[15]林一峰,魏合伟,蔡桦等.骨康及其含药血清中类性激素样物质含量的测定[J].中医药学刊,2003,21(5)：663-664.
[16]魏合伟,李钊,庄洪等.中药骨康含药血清对TNF-α致大鼠成骨细胞凋亡的影响[J].中医正骨,2005,17(3)：6-8.
[17]魏合伟,李钊.骨康含药血清对新生大鼠成骨细胞碱性磷酸酶活性的影响[J].中医药学刊,2005,23(1)：77-78.
[18]林一峰,刘庆思.骨康含药血清对成骨细胞PDGF-AA表达影响的实验研究[J].中国骨质疏松杂志,2006,12(5)：459-461.
[19]MarcJ, PrezeljJ, KomelR, et al. Association of vitamin-D receptor gene polymorphism with bone mineral density in Slovenian postmenopausal women[J]. Gynecol Endocrinol,2000; 14(1):60-64.
[20]Munger RG, CerhanJR, ChivBC. Prospective study of dietary protein in take and risk of hip fracture in postmenopausal women[J]. Am J Clin Nutr,1999; 69(1):147-152.
[21]Bailey, D. A., H. A. McKay, R. L. Mirwald, P. R. E. Crocker, et al. A six-year longitudinal study of the relationship of physical activity to bone mineral accrual in growing children:the University of Saskatchewan Bone Mineral Accrual Study [J]. Bone Miner Res,1999:14(6):1672.
[22]Blum M.Harris SS, Must A, et al. Leptin body composition and bone mineral density in preemenopausal women[J]. Calcif Tissue Int,2003;Apr14[epub ahead of print].
[23]Yahata Y, Aoyagi K,Okano K,et al. Mineral density,body mass index and lifestyle among postmenopausal Japanese women:relationship of body[J]. Tohoku J Exp Med,2002,196 (3):123-129.
[24]郭永忠,张峰.尿脱氧吡啶啉时新的骨吸收生化指标[J].医学综述,2000;6(1)：7-9.
[25]陶耕,蔡俊峰,李永加.绝经后妇女血清骨代谢生化指标的变化及意义[J].福建医药杂志,2003：25(1)：26-27.
[26]Vanderschueren D, VanHerck E, Suiker AMH, et al. Bone and mineral metabolism in aged rats:Short and long term effects of androgen deficiency[J]. Endocrinology,1992; 130: 2906-2916.
[27]周维,周丽萍,彭文湃.HRT加用雄激素对绝经后妇女骨代谢影响的探讨[J].中国妇幼保健,2004;19(1)：16-18.
[28]冯有辉,许碧连,何康等.大鼠骨量影响因素的灰色关联分析[J].中国新医药,2004;3(10)：43-44.
[29]Drake FH Dedds RA, James IE, et al. Cathepsin K, but not cathepsin B, L, or S, is abundantly expressed in human osteoclests[J]. Biol Chem,1996,271(21):12511-12516.
[30]RamazaT, Goto T, Kamiya T, et al. Study of immunoelectren micm-scopic localization of cathepsin K in osteoclasts and other bone eeHsinthemousefemur[J]. Bone,1998,23(6): 499-509.
[31]郭凌岑,龚健.绝经后骨质疏松症治疗进展[J].中国妇产科临床杂志,2006,7(6)：469-470.
[32]杨玲,殷晓进.锶与骨矿代谢[J].中国骨质疏松杂志,2004,3(8)：384-386.
[33]刘忠厚,潘子昂,王石麟,等.骨骼生长衰老规律和原发性骨质疏松预诊的研究[J].中国骨质疏松杂志,1995(1)：1-7.
[34]丁桂芝.从骨矿含量变化规律看肾主骨理论的科学性[J].湖北中医杂志,1991,13(2)：27-29.
[35]王大健,王爱坚, 黄李平,等.探讨老年肾虚证与骨密度的关系[J].上海中医药杂志,2002,36(9)： 35-36.
[36]陈训华,郭振芳,张万强.骨丢失与肾虚证的相关研究[J].中国中医药信息杂志,2002,9(10)： 21-22.
[37]朱小华,赵仓焕.从脾胃论治骨质疏松症[J].新中医,2004,36(12)： 3-4.
[38]孟晓东.补肾健脾养胃法治疗骨质疏松症的临床观察[J].吉林中医药,2004,24(11)29.
[39]袁静,章薇,金华,等.养血调肝方对绝经后骨质疏松症影响的实验研究[J].中国中医骨伤科杂志,2008,16(9)32-34.
[40]赵治友,邬亚军.骨质疏松症的中医辨证思路与治法研究[J].浙江中医药大学学报,2007,31(3)：275-276.
[41]徐元雯.管窥肝郁证的现代研究[J].江西中医学院学报,2007,19(2)：99-100.
[42]文哲双,王志忠,朱毅.肝郁患者血清T、E2、PRL检测及其临床意义[J].湖北中医学院学报,2000,2(2)：27-29.
[43]滕秀香.122例卵巢早衰患者中医证候分析及致病因素调查[J].中国中医药信息杂志,2008,15(4)： 18-20.
[44]吴笛, 陈日辉,方锦鎏.调补肝肾法为主治疗老年性骨质疏松症31例[J].山东中医药大学学报,2008,32(2)：126-127.
[45]郭郡浩,蔡辉.从瘀论治原发性骨质疏松症研究进展[J].河北中医,2008,30(11)：1225-1227.
[46]眭承志,周军,刘志坤.绝经后骨质疏松症血瘀病机的客观初步论证[J].中医研究,2005,18(1)：30-33.
[47]熊辉,姚共和,祁开泽,等.强肾密骨液电渗对原发性骨质疏松症骨代谢的影响[J].中国中医骨伤科杂志,2002,10(2)：17-20.
[48]廖琳,黎学松,蔡全辉,等.补肾生髓法治疗绝经后骨质疏松症的临床研究[J].中国中医药信息杂志,2004,11(4)：287-289.
[49]张红.从补肾健脾法谈中医药对骨质疏松症的防治[J].时珍国医国药,2007,18(9)：2250.
[50]黄振俊,陈建新,白一冰.滋肾骨康丸治疗骨质疏松症的临床研究[J].生物技术通讯,2008,19(2)：263-264.
[51]咎强,朱超,屈强,等.强骨汤治疗肾虚型骨质疏松症56例[J].陕西中医,2006,27(8)：957-958.
[52]阎小萍,朱俊岭,颜珏,等.补肾强督方治疗强直性脊柱炎骨质疏松、骨量减少102例临床观察[J].中华中医药杂志,2007,22(8)：571-573.
[53]周忠民,安建武,张根印.双骨汤治疗骨质疏松性骨折48例[J].陕西中医,2006,27(12)：1503-1505.
[54]文朝,王新,方楚权,等.壮骨胶囊治疗绝经后骨质疏松症的临床观察[J].湖北中医杂志,2008,30(8)：15-16.
[55]罗换新,赵学文,冀海源,等.壮骨颗粒治疗原发性骨质疏松症的多中心随机对照[J].辽宁中医杂志,2008,35(7)：1037-1038.
[56]林一峰.补肾中药对绝经后骨质疏松症患者密度、血清骨保护素和肿瘤坏死因子a的影响[J].中国临床康复,2006,10(27)：51-53.
[57]刘海全,陈超.刘庆思教授治疗骨质疏松症经验介绍[J].新中医,2007,39(5)：14.
[58]邓伟民,崔伟历,贺扬淑,等.补肾壮骨冲剂对男性骨质疏松症患者骨矿含量和骨密度的影响：5年观察[J].中国临床康复,2005,9(11)：150-151.
[59]史晓,祁丽丽,杨文宏.补肾通络方治疗原发性骨质疏松症32例[J].陕西中医,2007,28(11)：1497-1499.
[60]黄永明,许少健,石宇雄,等.骨松安胶囊治疗绝经后骨质疏松症34例[J].陕西中医,2006,27(8)：954-956.
[61]马泉,刘瑞荣,杨印智.骨疏康治疗绝经后骨质疏松症86例[J].陕西中医,2004,25(12)：1096-1097.
[62]许旺,陈玉辰,张景凤.益肾养肝合剂治疗肝肾不足型绝经后骨质疏松症临床疗效观察[J].中草药,2005,36(6)：898-899.
[63]李茵,于高路,莫少强,等.灰关联分析及信息处理方法评价骨质疏松症复方中药治疗的用药规律[J].中国组织工程研究与临床康复,2007,11(35)：7065-7068.
[64]Koji Nogawa, Ikiko Tsuritani, Teruhiko Kido, et al. Mechanism for bone disease found in inhabitants environmentally exposed to cadmium:decreased serum 1 α,25- dihydroxy vitamin D level[J].Int Occup Environ Health,1987,59:21.
[65]Feldman SL, Cousin J. Influence of cadmium on the metabolism of 25-hydroxylchole calciferol in chicks[J]. Nutr Re p Int,1973,8:251.
[66]Lorentzon R., Larsson S. E.. Vitamin D metabolism in rats at low and normal calcium intake and the effect of cadmium exposure[J]. Physical Science and Molecular Medicine, 1977,53:439.
[67]Chalkley S R, Richmond J, Bar It rop D. Measurement of vitamin D3 metabolites in smelter workers ex posed to lead and cadmium[J]. Occup Environ Med,1998,55:446.
[68]Ikiko Tsuritani, Ryumon Honda, Masao Ishizaki, et al. Impairment of vitamin D metabolism due to environmental cadmium exposure, and possible relevance to sex related to the bone damage[J]. Toxicol and Environ Health,1992,37:519.
[69]Cummings SR, Browner WS, Bauer D, et al. Endogenous hormones and the risk of hip and vertebral fractures among older women. Study of Osteoporotic Fractures Research Group[J]. N Engl J Med,1998,339:733-738.
[70]Melin AL, Wilske J, Ringerta H, et al. Vitamin D status, parathyroid function and femoral bone density in an elderly Swedish population living at home[J]. Aging Milano, 1999,11:200-207.
[71]Bettica P, Bevilacqua M, Vag o T, et al. High prevalence of hypovitaminosis D among free living postmenopausal women referred to an osteoporosis outpatient clinic in northern Italy for initial screening[J]. Osteoporos Int,1999,9:226-229.
[72]Gallagher JC, Fowler SE, Detter JR, et al. Combination treatment with Estrogen and calcitriol in the prevention of age related bone loss[J]. Clin Endocrinol Metab, 2001,86:3618-3628.